Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ2 | O43526 | 1/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19973145 | 0.84 | KCNQ2 (0.31) | KCNQ2ADRA1DADRA1AADRA1BKCNH2 | |
| SCHEMBL13059142 | 0.80 | CYP11B2 (0.33) | KCNQ2ADRA1DADRA1AADRA1BKCNH2 | |
| Bromide SCHEMBL844270 | 0.79 | CYP11B2 (0.32) | KCNQ2ADRA1DADRA1AADRA1BKCNH2 | |
| SCHEMBL16998697 | 0.74 | KCNQ2 (0.36) | KCNQ2ADRA1DADRA1AADRA1BKCNH2 | |
| SCHEMBL14157127 | 0.72 | KCNQ2 (0.35) | KCNQ2ADRA1DADRA1AADRA1BKCNH2 | |
| SCHEMBL14879606 | 0.72 | LOXL2 (0.48) | KCNQ2ADRA1DADRA1AADRA1BKCNH2 | |
| SCHEMBL10079569 | 0.72 | CYP11B2 (0.38) | KCNQ2ADRA1DADRA1AADRA1BKCNH2 | |
| SCHEMBL844970 | 0.72 | KCNQ2 (0.35) | KCNQ2ADRA1DADRA1AADRA1BKCNH2 | |
| Hydrochloric Acid SCHEMBL18422121 | 0.70 | KCNQ2 (0.34) | KCNQ2ADRA1DADRA1AADRA1BKCNH2 | |
| SCHEMBL13724816 | 0.69 | CYP11B2 (0.34) | KCNQ2ADRA1DADRA1AADRA1BKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-06 | — | — | US | disclosed |
| US-12459920-B2 | Targeted protein degradation | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-04 | — | — | US | disclosed |
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-07-31 | — | — | US | disclosed |
| WO-2025024521-A1 | SUBSTITUTED PIPERIDINEDIONES FOR TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| US-11571423-B2 | Small molecule modulators of human sting | CURADEV PHARMA LIMITED (GB) | 2023-02-07 | — | — | US | disclosed |
| US-11571423-B2 | Small molecule modulators of human sting | CURADEV PHARMA LIMITED (GB) | 2023-02-07 | — | — | US | disclosed |
| EP-3642198-B1 | SMALL MOLECULE MODULATORS OF HUMAN STING | CURADEV PHARMA LTD (GB) | 2022-03-16 | — | — | EP | disclosed |
| EP-3642198-B1 | SMALL MOLECULE MODULATORS OF HUMAN STING | CURADEV PHARMA LTD (GB) | 2022-03-16 | — | — | EP | disclosed |
| US-20200147083-A1 | SMALL MOLECULE MODULATORS OF HUMAN STING | CURADEV PHARMA LIMITED (GB) | 2020-05-14 | — | — | US | disclosed |
| US-20200147083-A1 | SMALL MOLECULE MODULATORS OF HUMAN STING | CURADEV PHARMA LIMITED (GB) | 2020-05-14 | — | — | US | disclosed |
| US-9040708-B2 | Pesticidal compounds | SYNGENTA LIMITED (GB) | 2015-05-26 | — | — | US | disclosed |
| US-20140296067-A1 | PESTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2014-10-02 | — | — | US | disclosed |
| US-20140296067-A1 | PESTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2014-10-02 | — | — | US | disclosed |
| US-20140296067-A1 | PESTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2014-10-02 | — | — | US | disclosed |
| EP-2773617-A1 | PESTICIDAL COMPOUNDS | Syngenta Participations AG (CH) | 2014-09-10 | — | — | EP | disclosed |
| WO-2013064521-A1 | PESTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013064521-A1 | PESTICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2013-05-10 | — | — | WO | disclosed |
| EP-2432776-A1 | METHYL SULFANYL PYRMIDMES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS | Chlorion Pharma, Inc. (CA) | 2012-03-28 | — | — | EP | disclosed |
| US-20100298336-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | UNIVERSITE LAVAL (CA) | 2010-11-25 | — | — | US | disclosed |
| WO-2010132999-A1 | METHYL SULFANYL PYRMIDMES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS | CHLORION PHARMA, INC. (CA) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298336-A1 | PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS | TYMS, P2RX2, TYMP | KCNQ2 1050/4885ADRA1D 3447/4885ADRA1A 2833/4885 |
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | KCNQ2 3509/4885ADRA1D 3573/4885ADRA1A 2554/4885 |
| US-12459920-B2 | Targeted protein degradation | NEK7, NEK1, RIPK1 | KCNQ2 3509/4885ADRA1D 3581/4885ADRA1A 2565/4885 |
| US-11571423-B2 | Small molecule modulators of human sting | STING1, IRF3, CGAS | KCNQ2 3746/4885ADRA1D 3610/4885ADRA1A 3241/4885 |
| US-20140296067-A1 | PESTICIDAL COMPOUNDS | C5, CBR3, C3AR1 | KCNQ2 794/4885ADRA1D 347/4885ADRA1A 398/4885 |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | KCNQ2 3509/4885ADRA1D 3573/4885ADRA1A 2554/4885 |
| US-20200147083-A1 | SMALL MOLECULE MODULATORS OF HUMAN STING | STING1, IRF3, CGAS | KCNQ2 3746/4885ADRA1D 3610/4885ADRA1A 3241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.